Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on Monday, December 23, 2013, to provide an update on its clinical trials of PB272 (neratinib) in cancer patients with activating HER2 mutations. This includes the Company’s ongoing trials of neratinib in (1) patients with HER2 mutated non-small cell lung cancer; (2) patients with HER2-negative breast cancer who have a HER2 mutation; and (3) patients with solid tumors who have an activating HER2 mutation.
Help employers find you! Check out all the jobs and post your resume.
